JLC-062

N/A

Report date: 2026/05/09 20:00:18

Base Information

Drug NameJLC-062

Drug Alias NameJLC062

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)

Mechanisms of ActionAnti-CD276Anti-Programmed death-ligand 1

TargetsCD276 antigenProgrammed death-ligand 1

Therapy Area/IndicationsSolid tumours

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesJecho Laboratories Inc

China Registration ClassN/A

Develop Information

Active CompaniesJecho Laboratories Inc

Inactive CompaniesN/A

Active IndicationsSolid tumours

Inactive IndicationsN/A

Other Information

ATC CodeN/A